compar favor almost med-tech compani updat
estim follow call account disclosur made
call model year year revenu growth growth
y/i revenu growth ep
financi flexibl spend time uncertainti choos
exactli increment spend mostli cog see reason
alter outlook adjust increas interest expens model
walk move part
noth call chang view one best posit
compani med-tech yet see benefit think
inevit govern stockpil essenti suppli salin last month
shelf bax pipelin remain robust reiter buy rate po base
ep roll
say growth lower two main reason advanc surgeri sale
high singl digit exclud seprafilm acquisit around
run rate basi today could rang view ii
pd periton dialysi growth low doubl digit could less
new patient start may suffer temporarili issu clearli covid relat
temporari real structur tailwind bax pd divis
beyond gross benefit covid relat demand across sever
busi anticip need think gross benefit
number go higher probabl stay less set revenu
teen global higher us sell manufactur
unabl access new pump account current posit hold
share market see high demand bax acut care dialysi busi see demand
well access suppli us given sourc challeng capac
constraint expect busi stay per quarter
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
baxter manufactur product use deliveri
fluid drug patient across
continuum care includ iv
steril solut administr set premix
drug drug-reconstitut system iv nutrit
product infus pump inhal
servic relat pharmaci compound
drug formul packag technolog
believ baxter opportun grow ep
higher end peer given compani
margin expans opportun lever
balanc sheet expect put balanc
sheet work set stage
improv revenu growth beyond
rate stock buy
price object base earn multipl ep
estim multipl peer think justifi given low doubl
digit ep growth profil long term potenti drive upsid ep
balanc sheet activ upside/downsid risk po margin expand
revenu grow faster/slow rate expect strateg activ
view posit neg
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
